Biopharmaceutical Manufacturing, Upstream, Downstream …
2024年12月19日 · News on the biopharmaceutical manufacturing industry, focusing on biologics, technology, upstream/downstream processing, cell culture and regulations
News - biopharma-reporter.com
2024年12月17日 · News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
How will the Biosecure Act impact the pharma industry?
2024年10月8日 · But what does the Act mean for the biotech and pharma industry and how can companies best prepare for any impacts on future business? The Biosecure Act was first proposed by the US government late last year due to concerns about national security and how genetic and other biological data could be misused by foreign adversarial governments with a focus on China.
BioPharmaReporter gets a new look
2024年11月26日 · We’re thrilled to announce that we have migrated BioPharmaReporter to a new platform. Our expert coverage of the sector won’t change, but we’ve tweaked the look and feel of the site to bring you improved navigation, more content-rich articles, enhanced search capabilities and a better browsing experience.
Cell and gene therapy will be top industry trend for pharma in 2024
2024年1月8日 · Healthcare industry professionals scored cell and gene therapy (CGT) as the industry trend to have the greatest impact on the pharmaceutical industry in 2024, in a recent survey launched by data and analytics firm GlobalData.
Trends in biosimilars: Regulatory approvals in 2024
2024年7月24日 · The biosimilars market is rapidly growing as global demand for biosimilars continues to grow. The global biosimilar market is estimated to reach a size of $43.8 billion by the end of 2024, and to grow over $100 billion in the next 10 years.. Biologics are expensive medications, which is driving up the popularity of biosimilars as a more cost-effective alternative.
Biohaven’s myostatin inhibitor fails in phase 3 spinal muscular …
2024年11月26日 · Biohaven announced this week that its phase 3 trial of taldefgrobep alfa, a recombinant protein targeting myostatin, had failed to meet its primary endpoint in patients with spinal muscular atrophy.
Thermo Fisher - accelerating the shift towards precision medicine
2024年10月22日 · Thermo Fisher’s John Lesica discusses how mass spectrometry technology enables scientific breakthroughs in genomics and proteomics to provide valuable insights for drug discovery and development.
Speed, flexibility and innovation: Rethinking the way the …
2021年11月29日 · CRB’s newly released biopharma market outlook: Horizons: Life Sciences, is fueled by survey insights from more than 500 pharma representatives on key issues facing their organizations. “The report is looking at all the different disruptions within the life science industry over the past 12 months, with an emphasis on mRNA and warp speed delivery, as well as other emerging trends,” said ...
Janssen’s antibody drug shows phase 2 potential in rheumatoid …
2023年11月9日 · The proof-of-concept trial, dubbed IRIS-RA, is the first to investigate a treatment for rheumatoid arthritis that blocks a protein called neonatal Fc receptor (FcRn). The antibody drug nipocalimab, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, has shown early promise for treating rheumatoid arthritis (RA) in a phase 2a trial.